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Adenovirus-Mediated Gene Therapy Enhances Parainfluenza Virus 3
Infection in Neonatal Lambs
Abstract
Parainfluenza viruses are a common cause of seasonal respiratory disease, but in high-risk individuals (e.g.,
young children) these viruses can cause severe clinical manifestations that require hospitalization. Beta-
defensins are a subclass of antimicrobial peptides with antiviral activity. Use of adenovirus-mediated beta-
defensin gene expression has been proposed as therapy for chronic bacterial infections commonly seen in
cystic fibrosis patients; however, its use during parainfluenza virus 3 (PIV3) infection has not been evaluated.
The hypothesis in this experiment was that adenovirus expression of human beta-defensin 6 (HBD6) would
diminish concurrent PIV3 infection in neonatal lambs. The group infected with adenovirus HBD6 and PIV3
had increased levels of pulmonary neutrophil recruitment compared to those for the group infected with PIV3
or PIV3 and adenovirus, with an increased respiration rate and body temperature late in the course of the
PIV3-adenovirus HBD6 infection. Interestingly, the adenovirus-treated groups had higher levels of
immunohistochemical staining for PIV3 and syncytial cell formation than the group infected with PIV3,
suggesting that treatment with the adenovirus vector, regardless of whether it was carrying a target gene,
exacerbated the PIV3 infection. The levels of expression of mRNA for antimicrobial surfactant proteins A and
D and sheep beta-defensin 1 were increased by PIV3 and adenovirus treatment, and the increased levels of
expression roughly corresponded to the degree of inflammation. While pulmonary administration of a high-
dose adenovirus vector has been associated with undesirable inflammation, this is the first study to show that
it can exacerbate concurrent viral infection, a concern that needs to be addressed for future studies of
adenovirus in the lung. Additionally, this study showed that adenovirus-mediated HBD6 expression increases
neutrophil recruitment, a recently described attribute of beta-defensins, with mild accentuation of PIV3
activity and inflammation.
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Infection in Neonatal Lambs
David K. Meyerholz,1* Branka Grubor,1 Jack M. Gallup,1 Howard D. Lehmkuhl,2
Richard D. Anderson,3 Tatjana Lazic,1 and Mark R. Ackermann1
Department of Veterinary Pathology, Iowa State University,1 and the Respiratory Diseases of Livestock, National Animal Disease
Center, Agricultural Research Service, U.S. Department of Agriculture,2 Ames, Iowa, and ViraQuest, Inc., North Liberty, Iowa3
Received 26 April 2004/Returned for modification 3 June 2004/Accepted 11 June 2004
Parainfluenza viruses are a common cause of seasonal respiratory disease, but in high-risk individuals (e.g.,
young children) these viruses can cause severe clinical manifestations that require hospitalization. Beta-
defensins are a subclass of antimicrobial peptides with antiviral activity. Use of adenovirus-mediated beta-
defensin gene expression has been proposed as therapy for chronic bacterial infections commonly seen in cystic
fibrosis patients; however, its use during parainfluenza virus 3 (PIV3) infection has not been evaluated. The
hypothesis in this experiment was that adenovirus expression of human beta-defensin 6 (HBD6) would
diminish concurrent PIV3 infection in neonatal lambs. The group infected with adenovirus HBD6 and PIV3
had increased levels of pulmonary neutrophil recruitment compared to those for the group infected with PIV3
or PIV3 and adenovirus, with an increased respiration rate and body temperature late in the course of the
PIV3-adenovirus HBD6 infection. Interestingly, the adenovirus-treated groups had higher levels of immuno-
histochemical staining for PIV3 and syncytial cell formation than the group infected with PIV3, suggesting that
treatment with the adenovirus vector, regardless of whether it was carrying a target gene, exacerbated the PIV3
infection. The levels of expression of mRNA for antimicrobial surfactant proteins A and D and sheep beta-
defensin 1 were increased by PIV3 and adenovirus treatment, and the increased levels of expression roughly
corresponded to the degree of inflammation. While pulmonary administration of a high-dose adenovirus vector
has been associated with undesirable inflammation, this is the first study to show that it can exacerbate
concurrent viral infection, a concern that needs to be addressed for future studies of adenovirus in the lung.
Additionally, this study showed that adenovirus-mediated HBD6 expression increases neutrophil recruitment,
a recently described attribute of beta-defensins, with mild accentuation of PIV3 activity and inflammation.
Parainfluenza virus 1 and parainfluenza virus 3 (PIV3) are
enveloped, single-stranded, negative-sense RNA viruses of the
family Paramyxoviridae and are important, ubiquitous causes of
seasonal respiratory disease. Infection in a healthy individual is
localized primarily to the upper respiratory tract and is often
self-limiting (13, 27). However, human parainfluenza viruses
can cause more serious respiratory disease such as severe la-
ryngotracheitis (croupy cough), bronchiolitis, and pneumonia,
which may lead to hospitalization and, on rare occasions, death
(15). Risk factors for severe manifestations of parainfluenza
virus infection include primary lung disease (e.g., cystic fibrosis
or asthma), immunocompromise (e.g., transplant recipients),
young age, and old age (9, 15, 16). Parainfluenza viruses, along
with other viruses, are increasingly recognized in exacerbations
of cystic fibrosis lung disease and may predispose individuals to
secondary bacterial infections, including infections with
Pseudomonas aeruginosa, which is a persistent problem in the
lungs of individuals with cystic fibrosis (37). Young children
and infants with cystic fibrosis are at increased risk for lower
respiratory tract infections caused by these ubiquitous viruses,
resulting in increased hospitalization rates and chronic lung
damage (16, 36).
Defensins are a conserved class of antimicrobial peptides
characterized by a cationic charge, antimicrobial activity, and
six to eight highly conserved cysteine residues that form in-
tramolecular disulfide bonds. There are three families of de-
fensins, the alpha-, beta-, and theta-defensins, each of which is
characterized by the organization of the intramolecular disul-
fide bonds (39). Beta-defensins are a class of cationic antimi-
crobial peptides that are produced primarily in the epithelium
at mucosal sites, including the lungs (30). There are more than
30 putative human beta-defensin genes, and many of the prod-
ucts of those genes that have already been characterized have
wide spectra of microbicidal activities against bacteria, fungi,
and enveloped viruses (1, 31). The antiviral action of beta-
defensins is thought to be through disruption of the viral en-
velope; however, recent work with alpha-defensins suggests
that the antiviral activity may also involve intracellular cell
signaling for the inhibition of viral replication (6, 30). Inacti-
vation of beta-defensins by the altered local environment (e.g.,
altered salinity or the presence of airway surface liquid) has
been suggested to contribute to the increased susceptibilities of
cystic fibrosis patients to pulmonary infection (3, 11).
Perinatal lambs are commonly used as models for pulmo-
nary disease research, including research involving gene ther-
apies (19, 26). Perinatal lambs are susceptible to ovine PIV3
isolates, which have genomic and antigenic properties similar
to those of human PIV3 isolates and which cause spontaneous
respiratory disease and lesions in sheep (20, 33). Previous work
with the human bronchial xenograft model with adenovirus
(Ad)-mediated gene therapy and overexpression of a catheli-
* Corresponding author. Mailing address: Department of Veteri-
nary Pathology, Iowa State University, 2740 Veterinary Medicine,
Ames, IA 50011-1250. Phone: (515) 294-7307. Fax: (515) 294-5423.
E-mail: dmeyerho@iastate.edu.
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cidin antimicrobial peptide (LL-37 [also known as hCAP-18])
showed success in killing bacteria, suggesting that they may be
useful for antimicrobial gene therapy in patients predisposed
to PIV3 infections (4); however, evaluation of antimicrobial
peptide gene therapy as a way to diminish viral infection has
not been applied. Human beta-defensin 6 (HBD6), a recently
described beta-defensin selectively expressed in the epididy-
mis, was chosen as the antimicrobial peptide in this model due
to its lack of expression in the human lung or in sheep (38).
The hypothesis of this study was that HBD6 gene expression in
the neonatal lamb lung would diminish concurrent PIV3 in-
fection in neonatal lambs.
MATERIALS AND METHODS
Animals. All animal studies were approved by the Iowa State University
Animal Care and Use Committee. Neonatal lambs (n  20) were obtained from
Iowa State University’s Laboratory Animal Resources. At 3 to 5 days after birth
(which allowed time for acclimation) the lambs were inoculated intratracheally
with two 20-ml volumes at approximately 30-min intervals. The order and com-
position of the inoculum for each group (n  4) were as follows: group A, sterile
medium and sterile medium (control group); group B, sterile medium and PIV3
(PIV3 group); group C, Ad vector (no gene insertion) and PIV3 (PIV3/Ad
group); and group D, Ad HBD6 and PIV3 (PIV3/Ad/HBD6 group). At day 7 of
infection the lambs were euthanized by intravenous injection of sodium pento-
barbital for collection of tissues. From our preliminary data this time was chosen
because it is the time of significant lesion development and active viral clearance.
An additional group of lambs were given an intratracheal inoculation (20 ml) of
sterile medium (n  2) or Ad HBD6 (n  2) containing a lacZ gene insert for
cellular localization of transfection. These lambs were euthanized on day 4 of
infection, which was near the peak amount for pulmonary Ad vector gene
expression (10).
Viruses. The ovine isolate of PIV3 was grown to 107.8 50% tissue culture
infective doses/ml (20 ml per lamb), as described previously (20). The replica-
tion-defective human Ad 5 vector had a cytomegalovirus promoter and was
commercially acquired with the human HBD6 gene (identification no. 2602699;
IMAGE Consortium), the HBD6 gene with a lacZ reporter gene, or no gene
insert (ViraQuest, Inc., North Liberty, Iowa). Ad (no gene insert) and Ad/HBD6
had a deletion of the gene for protein E1 (nucleotides 358 to 3328), and the
Ad/HBD6/lacZ insert for 5-bromo-4-chloro-3-indolylphosphate (X-Gal) staining
had deletions at nucleotides 358 to 3328 and nucleotides 28592 to 30470, with the
concurrent loss of protein E1 and E3 functions. Each lamb received approxi-
mately 1012 virus particles in 20 ml of sterile saline.
Clinical parameters. The lambs were assessed daily for different clinical pa-
rameters. Body weight, temperature, and respiratory rate were taken at the same
time of day, following the morning feeding. The lambs were treated daily with
antibiotic (ceftiofur at 10 mg/day subcutaneously) to prevent complications as-
sociated with secondary bacterial infections (34).
Tissues. Lung tissue was consistently collected from the cranial and caudal
lobes on the left and right sides. The tissue samples were placed in 10% neutral
buffered formalin and processed routinely for hematoxylin-eosin staining or
immunohistochemistry. In addition, lung tissue was snap-frozen in liquid nitro-
gen for RNA isolation and real-time fluorogenic PCR.
RNA isolation. RNA isolation and cDNA production were performed as
described previously (24). Briefly, 0.3 g of tissue and 3 ml of Trizol reagent
(Invitrogen) were homogenized for 30 s, and the homogenate was allowed to sit
for 5 min at room temperature. Chloroform (0.6 ml) was added, and the mixture
was shaken vigorously for 15 s and then allowed to sit for 3 min at room
temperature. This mixture was microcentrifuged for 10 min at 4°C, the resulting
top aqueous layer was retrieved and mixed with isopropanol (1.5 ml), and the
mixture was allowed to sit for 10 min at room temperature. The solution was
again microcentrifuged for 10 min at 4°C, the aqueous-isopropanol layer was
removed, and the visible pellet was resolubilized in nuclease-free high-pressure
liquid chromatography-grade water containing 0.1 mM EDTA. Spectrophoto-
metric measurements (detection at absorbances of 260 and 280 nm with 1:40
sample dilutions) of each RNA sample were then taken to assess the isolates for
purity and quantity.
cDNA production. The RNA samples were treated with a commercially avail-
able DNase (RQ1 RNase-free DNase; Promega) to remove potential genomic
DNA contamination. Immediately after this, reverse transcription was per-
formed with the reagents available in a commercially available kit (TaqMan
reverse transcriptase reagents; PE Applied Biosystems), according to the direc-
tions of the manufacturer. Briefly, 2 g of DNase-treated RNA from each
sample and control was added to a reaction mixture which contained final
concentrations of 1 TaqMan reverse transcriptase buffer, 5.5 mM MgCl2, 2 mM
deoxyribonucleoside triphosphate mixture (500 M each deoxyribonucleoside
triphosphate), 2.5 M random hexamers, 1.25 U of murine leukemia virus
reverse transcriptase per l, 0.4 to 0.8 U of RNase inhibitor per l, and high-
pressure liquid chromatography-grade water. The following thermocycler condi-
tions were then used: 10 min at 25°C, 30 min at 48°C, and 5 min at 95°C. The
resulting cDNA was stored in nuclease-free microcentrifuge tubes at 20°C.
Primer and probe design. Sequence-specific oligonucleotide primers and a
fluorescent probe were designed with software (ABI Prism Primer Express,
version 1.5; PE Applied Biosystems), according to the suggestions of the software
manufacturer. The similarities of the resultant potential primer and probe se-
quences to DNA sequences available in databases were determined by use of the
search tool BLAST (Basic Local Alignment Search Tool, version 1.4; National
Center for Biotechnology Information), and only unique sequences were used
TABLE 1. Primer and probe sequences for expression of mRNAs for SP-A, SP-D, SBD1, and HBD6
Primer or probe specificity and primer or probe Sequencea
SP-A
Forward ...................................................................5-TGACCCTTATGCTCCTCTGGAT-3
Reverse ....................................................................5-GGGCTTCCAAGACAAACTTCCT-3
Probe........................................................................5-6FAM-TGGCTTCTGGCCTCGAGTGCG-TAMRA-3
SP-D
Forward ...................................................................5-ACGTTCTGCAGCTGAGAAT-3
Reverse ....................................................................5-TCGGTCATGCTCAGGAAAGC-3
Probe........................................................................5-6FAM-TTGACTCAGCTGGCCACAGCCCAGAACA-TAMRA-3
SBD1
Forward ...................................................................5-CCATAGGAATAAAGGCGTCTGTGT-3
Reverse ....................................................................5-CGCGACAGGTGCCAATCT-3
Probe........................................................................5-6FAM-CCGAGCAGGTGCCCTAGACACATGA-TAMRA-3
HBD6
Forward ...................................................................5-CCC CAG CCA AGA ATG CAT-3
Reverse ....................................................................5-TCA TTT TTC CCG CAA TTG TTC-3
Probe........................................................................5-6FAM-TTTTGATGAGAAATGCAACAAACTTAAAGGGACA-TAMRA-3
a 6FAM, 6-carboxyfluorescein (fluorescent reporter dye); TAMRA, 6-carboxytetramethylrhodamine (fluorescent quencher dye).
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for primer and probe design (Table 1). Sequence-specific oligonucleotide prim-
ers and a fluorescent probe for detection of cDNA corresponding to the endog-
enous reference gene, 18S rRNA, to which target cDNA levels were normalized,
were purchased commercially (TaqMan rRNA control reagents; PE Biosystems).
PCR. The 96-microwell plates were designed to enable testing of two replicates
of both the target gene and the endogenous 18S rRNA of a 1:5 dilution of cDNA
from all lambs, a negative control (diethyl pyrocarbonate-treated water), and five
progressive 1:5 dilutions of cDNA from a control sheep for generation of the
standard curve. On each plate, the wells with the target gene and the endogenous
reference rRNA were run simultaneously by PCR with the tissues represented on
that plate. The plate was run in a sequence detection system (GeneAmp 5700,
version 1.3; PE Applied Biosystems) under conditions identical to those used in
the optimization and validation tests. The resultant data gathered by the detec-
tion system were exported from the machine to a floppy disk, and all final data
processing was performed by using a departmentally designed Excel software file
to compare the target to the reference cDNA signals in order to create graphs of
the relative levels of mRNA expression.
PIV3 immunohistochemistry. Formalin-fixed, paraffin-embedded sections
were deparaffinized in xylene, followed by passage through a series of alcohol
baths; and pronase E (0.1 g of protease XIV and 0.1 g of CaCl2 per 100 ml of
Tris-buffered saline [pH 7.4]) was applied for antigen retrieval. After the sections
were washed (with phosphate-buffered saline), the background blocker (20%
normal swine serum), followed by primary antibody (goat polyclonal anti-bovine
PIV3, 1:1,000 [Veterinary Medical Research & Development, Inc.]), was applied
to the tissues. These sections were washed, hydrogen peroxide (3% in methanol)
was applied to block endogenous peroxidases, and the sections were washed
again. Secondary antibody (1:400 biotinylated rabbit anti-goat antibody) was
applied, followed by washing in supersensitive-horseradish peroxidase and chro-
mogen (Vector Red; Vector). The slides were counterstained with hematoxylin,
dehydrated in a series of alcohol baths and then with xylene, and placed under
a coverslip, to which Permount was applied.
Morphometry. Measurement of microscopic morphological changes, including
cellular staining, rate of mitosis, neutrophil density, and syncytial cell formation,
were assessed by a pathologist blinded from the study using a grid (18). Cranial
and caudal lung lobes (bilaterally) were used for the study. For each slide, the
pathologist randomly chose 10 sites under low power, and then the selected
morphological alteration was counted under high power. This was done for each
segment of lung, and the results were totaled and averaged for the grid area
(13,000 or 52,000 m2).
Ad distribution. OCT-embedded frozen sections were cut to a thickness of 6
m and placed in a bath of 4% formaldehyde for 5 min, and the slides were then
washed twice in Hanks balanced salt solution (HBSS). X-Gal staining solution
(20 mg of 5-bromo-4-chloro-3-indolyl--D-galactopyranoside per ml of N,N-
dimethyl formamide) was added (20 l/ml) to a fresh solution of 5 mM potas-
sium ferricyanide–5 mM potassium ferrocyanide–2 mM magnesium chloride in
HBSS for the final X-Gal working solution. The slides were then exposed to the
final X-Gal working solution for 10 h at 37°C. The slides were washed in HBSS
counterstained with nuclear fast red and placed under a coverslip. Sections were
then examined for cells that stained blue, which is indicative of lacZ expression
(23).
Statistics. For assessment of clinical and fluorogenic real-time PCR data,
significance was determined to be a P value of 0.05. Nonparametric Wilcoxon
tests were used to assess samples of unequal sizes for statistical differences. t tests
that assumed unequal variances were used to assess the means for groups of
equal sizes for differences.
RESULTS
The daily body temperatures showed early and late increases
through the course of infection. On day 2, the body tempera-
tures of all animals in the PIV3-infected groups were generally
increased, with the animals in the PIV3/Ad/HBD6 group hav-
ing a significantly higher temperature than those in the control
group (P  0.01) (Fig. 1). Starting on day 5 the animals in the
PIV3/Ad/HBD6 group had significantly increased body tem-
peratures compared with those of the animals in the control
group, and these continued throughout the duration of the
experiment (P  0.05). The animals in the PIV3 and PIV3/Ad
groups had moderately increased body temperatures that were
not statistically significant different except for those for the
animals in the PIV3 group on day 6 (P  0.01).
The respiration rate on day 2 was significantly higher in the
animals in the PIV3/Ad group (P  0.05) and moderately
elevated in the animals in the PIV3/Ad/HBD6 group (P 
0.08) compared to that in the animals in the PIV3 group (Fig.
2). By day 4 the respiration rates in the animals in the PIV3-
infected groups were generally elevated (P  0.05) compared
with those in the animals in the control group, except for an
increase that lacked statistical significance for the PIV3/Ad/
HBD6 group on day 6. Interestingly, on days 6 and 7 the
animals in the PIV3/Ad/HBD6 group had a slightly higher
respiration rate than those in the PIV3 or PIV3/Ad group.
Daily milk consumption (in liters per kilogram of body
weight) was evaluated to determine if there were any clinical
differences in appetite. For the duration of the experiment, the
animals in the PIV3, PIV3/Ad, and PIV3/Ad/HBD6 groups
had decreased (P  0.05) average milk consumption compared
FIG. 1. Body temperatures for the treatment groups. The animals
in the PIV3 group had significantly increased body temperatures com-
pared with those of the animals in the control group on day 6, while the
animals in the PIV3/Ad/HBD6 group had increased body tempera-
tures compared with those of the animals in the control group on days
2, 5, 6, and 7. , P  0.01 compared with the results for the controls;
, P  0.05 compared with the results for the controls.
FIG. 2. Respiration rates for treatment groups. On day 2 the ani-
mals in the PIV3/Ad group and the PIV3/Ad/HBD6 group (P  0.08)
had increased respiration rates compared to those for the animals in
PIV3 group. Starting on day 4 the animals in the PIV3-infected groups
had increased respiration rates compared to those of the control ani-
mals, with that for the animals in the PIV3/Ad/HBD6 group being
slightly higher on days 6 and 7. , P  0.05 compared with the results
for the controls; , P  0.05 compared with the results for the PIV3
group.
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to that for the animals in the control group, with no significant
difference among the PIV3-treated groups (Fig. 3).
The growth of the lambs (average daily gain, in kilograms
per day) during the experiment corresponded to the milk con-
sumption, with significantly decreased growth of the animals in
the PIV3 (P  0.05) and PIV3/Ad/HBD6 (P  0.05) groups
(Fig. 4). The animals in the PIV3/Ad group showed a similar
decrease in growth, but the decrease was not statistically sig-
nificant.
Grossly, the control lambs had no visible lesions, while the
lambs in the PIV3, PIV3/Ad, and PIV3/Ad/HBD6 groups had
a cranioventral to hilar distribution of multifocal plumb-red
consolidation. There was a slightly wider lesion distribution in
the lambs in the PIV3/Ad and PIV3/Ad/HBD6 groups com-
pared with that in the lambs in the PIV3 group. Microscopi-
cally, the PIV3-induced lesions consisted of a multifocal thick-
ening of the alveolar septa by macrophages and a small
number of lymphocytes, neutrophils, and plasma cells. The
bronchiolar lumens contained small aggregates of neutrophils
and sloughed cellular debris. Within these areas, the bronchio-
lar epithelium was thickened due to hyperplasia, with folds of
piled cells having pale cytoplasms, increased mitotic figures,
and infrequent syncytial cells. The animals in the PIV/3/Ad/
HBD6 group appeared to have relatively higher numbers of
neutrophils within the lungs compared to the numbers in the
lungs of the animals in the group inoculated with PIV3 alone.
To evaluate neutrophil recruitment to the lungs following
treatment, pulmonary neutrophil density was determined by
morphometry. The lungs of each of the PIV3-infected groups
had significantly increased (P  0.05) neutrophilic infiltrates
compared with the lungs of the controls (Fig. 5). In addition,
the PIV3/Ad/HBD6 group had a higher neutrophil count than
either the PIV3 or the PIV3/Ad group (P  0.05).
PIV3 immunohistochemistry produced no staining in the
control lungs, while cellular staining was present in the lungs of
all lambs in the PIV3-infected groups. This was characterized
by small granular red staining within the cytoplasm (Fig. 6).
Affected cells most often were epithelial cells of the distal
bronchi to terminal bronchioles. Morphometric quantification
of the cellular PIV3 immunostaining showed increased num-
bers of immunoreactive cells in the PIV3/Ad (P  0.05) and
PIV3/Ad/HBD6 (P  0.05) groups compared to the number in
the PIV3 group (Fig. 7).
The mitotic rate was significantly increased in all of the
PIV3-infected groups compared with that in the control group
(Fig. 8). No significant changes in the PIV3-infected groups
were evident. PIV3-induced syncytial cell formation was not
present in the control group but was present in all of the
PIV3-infected groups. The combined Ad gene therapy groups
had higher syncytial cell densities than the PIV3-infected
groups (P  0.05) (Fig. 9).
The Ad vector was localized by X-Gal staining to a small
number (5%) of individual epithelial cells of the bronchi and
terminal bronchioles (data not shown). This staining was not
seen in samples from two control lambs inoculated with sterile
medium.
Real-time fluorogenic PCR was used to assess the lambs for
transfection of HBD6 and for alterations in host SBD1, SP-A,
and SP-D mRNA. No amplification of HBD6 was detected in
the control groups (inoculated with PIV3/Ad) by the fluoro-
genic PCR, while all four of the HBD6-inoculated lambs had
late-cycle amplification, indicating weak HBD6 expression
(data not shown). Expression of SP-D in each PIV3-infected
group was significantly elevated compared with that in the
control group, and the levels of expression tended to increase
from the PIV3/Ad group to the PIV3/Ad/HBD6 group (Fig.
10). Similar trends in SP-A and SBD1 mRNA expression were
present, with statistically significant differences seen for the
levels of expression in the PIV3/Ad and PIV3/Ad/HBD6
groups combined compared with that in the PIV3 group for
both SP-A and SBD1 (P  0.05) (Fig. 11 and 12).
FIG. 3. Daily milk consumption for the treatment groups. All
PIV3-infected groups had similar decreases in milk consumption. , P
 0.05 compared with the results for the controls.
FIG. 4. Average daily weight gain for the treatment groups. The
animals in the PIV3 and PIV3/Ad/HBD6 groups had significant de-
creases in growth rates, while the animals in the PIV3/Ad group had a
slightly decreased growth rate compared to that of the control animals.
, P  0.05 compared with the results for the controls.
FIG. 5. Pulmonary neutrophil density in the treatment groups. All
PIV3-infected groups had higher neutrophil densities than the control
group. The PIV3/Ad/HBD6 group had increased neutrophil density
compared with those of the PIV3 and PIV3/Ad groups. , P  0.05
compared with the results for the controls; , P  0.05 compared with
the results for the PIV3 or PIV3/Ad group.
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DISCUSSION
The hypothesis of this study was that beta-defensin (HBD6)
expression during concurrent PIV3 infection would diminish
disease progression. Clinical parameters were monitored dur-
ing the course of infection, and day 7 of infection was chosen
for necropsy, as the lesions were usually marked and active
viral clearance was seen in the lambs (7, 20). All PIV3-infected
groups had clinical evidence of infection (e.g., elevated tem-
perature and tachypnea and depressed milk consumption and
growth), gross and microscopic lesions consistent with PIV3
infection, and immunohistochemical staining in PIV3-infected
animals only. Ad transfection was confirmed by X-Gal staining
of the Ad/HBD6/lacZ-infected airway epithelium on day 4 and
by HBD6 mRNA expression on day 7 of infection.
The animals in the Ad-treated groups (the PIV3/Ad and
PIV3/Ad/HBD6 groups) had increased temperatures and res-
piration rates on day 2 of infection. This was consistent with
previous work in which BALB/c mice showed increased levels
of the proinflammatory cytokines tumor necrosis factor-alpha
(TNF-) and interleukin-6 (IL-6) within even hours of in-
trapulmonary inoculation of human Ad 5 (40). TNF- and
IL-6 are endogenous pyrogens that account for the increased
body temperatures, and TNF- mediates bronchial and vascu-
lar smooth muscle contractility, which, along with pyrexia,
could have increased the respiratory rate (2, 35). Other clinical
alterations compared to the clinical conditions of the controls
were generally attributable to PIV3 infection. Of particular
interest was the fact that the animals in the Ad-treated groups
had increased staining of PIV3 and syncytial cell formation
FIG. 6. Immunohistochemistry for PIV3 in the PIV3 group (A),
PIV3/Ad group (B), and PIV3/Ad/HBD6 group (C). The PIV3/Ad and
animals in the PIV3/Ad/HBD6 group had increased cellular staining
compared with that for the animals in the PIV3 group. No staining was
detected for the animals in the control group (not shown). Magnifica-
tions, 400.
FIG. 7. Cellular PIV3 antigen staining in the treatment groups. The
PIV3/Ad and PIV3/Ad/HBD6 groups each had significant increases in
PIV3 antigen staining compared with that for the PIV3 group. The
control group had no staining. , P  0.05 compared with the results
for the PIV3 group.
FIG. 8. Mitotic rate in the treatment groups. The PIV3, PIV3/Ad,
and PIV3/Ad/HBD6 groups had similar significant increases in the
mitotic rate compared with that for the control group, with no signif-
icant differences among the PIV3-infected groups. , P  0.05 com-
pared with the results for the control group.
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compared with that in the animals in the PIV3 groups not
treated with Ad. Antigen staining occurs at sites of PIV3 pro-
tein synthesis, and syncytial cell formation is mediated by the
fusion protein and is regulated by the hemagglutinin-neura-
minidase protein; both indicators are by-products of PIV3 rep-
lication (28).
The increased immunostaining and syncytial cell formation
were both indicative of enhanced PIV3 activity (21, 28). This
novel finding suggests that pulmonary Ad-mediated gene ther-
apy can exacerbate concurrent PIV3 infection. Proteins of Ads,
including proteins E1A, E1B, and E3, have been shown to have
immunomodulating functions, most of which are immunosup-
pressing (17, 29). The vector used in this study had an E1
deletion, but the E3 gene was intact. E3 gene products inhibit
peptide processing for major histocompatibility complex
(MHC) I presentation; activation of nuclear factor-kappa beta
(NF-	); and apoptosis through the fatty acid synthase, TNF-
related apoptosis-inducing ligand, and TNF- pathways (5, 8,
17, 29, 32). Processing for MHC I presentation and apoptosis
of virus-infected cells are important mechanisms for viral
clearance, and the synthesis of antiviral type I interferon along
with other inflammatory mediators are mediated in part
through NF-	 activation. Early protein E3 inhibition of anti-
viral pathways could have allowed more enhanced PIV3 rep-
lication and infection. While the immunosuppressive effects of
the Ad E3 gene may participate in enhancing PIV3 infection,
the low level of cellular distribution of Ad suggests that this
may not be a significant component. Another mechanism for
enhanced PIV3 infection may be the general inflammatory and
cellular changes caused by the addition of the Ad vector. In
previous work, pretreatment with 4-ipomeanol similarly en-
hanced PIV3 activity in a calf model (21). The compound
4-ipomeanol is biotransformed in Clara cells into a free-radical
metabolite which causes necrotizing bronchiolitis and intersti-
tial pneumonia. The investigators that used the PIV3-infected
calf model hypothesized that 4-impomeanol may (i) suppress
pulmonary innate defenses, (ii) increase the number of suscep-
tible cells, or (iii) increase the levels of factors (e.g., proteases)
that enhance viral replication. Early immunosuppression by
Ad proteins and/or altered cellular susceptibility to PIV3 in-
fection and replication may contribute to this increased PIV3
activity in Ad-treated lambs. Further work needs to be done to
clarify and define the mechanism.
We further evaluated the levels of mRNA for innate anti-
microbial peptides and proteins to determine if Ad gene ther-
apy altered mRNA expression. SP-D levels were increased in
each PIV3-infected group compared with those in the control
group (P  0.05), with moderate increases in the PIV3/Ad/
HBD6 group compared with those in the PIV3/Ad and PIV3
groups. Similar trends were seen for SP-A and SBD1 mRNA,
with significant increases in the PIV3/Ad and PIV3/Ad/HBD6
groups combined compared with those in the PIV3 group (P 
0.05). Surfactant protein and beta-defensin mRNA expression
is partially regulated by the status of pulmonary inflammation
FIG. 9. Syncytial cell formation in the treatment groups. The
PIV3/Ad and PIV3/Ad/HBD6 groups combined had significantly
higher syncytial cell formation than the PIV3 group. , P  0.05
compared with the results for the PIV3 group.
FIG. 10. SP-D mRNA expression in the treatment groups. The
levels of expression were increased in the PIV3, PIV3/Ad, and PIV3/
Ad/HBD6 groups compared to those in the control group, with a
moderate increase in the PIV3/Ad/HBD6 group compared to that for
the PIV3/Ad group , P  0.05 compared with the results for the
control group.
FIG. 11. SP-A mRNA expression in the treatment groups. The
levels of SP-A mRNA expression in the PIV3/Ad and PIV3/Ad/HBD6
groups combined was significantly increased compared to that in the
PIV3 group. , P  0.05 compared with the results for the PIV3 group.
FIG. 12. SBD1 mRNA expression in the treatment groups. The
levels of SBD1 mRNA expression in the PIV3/Ad and PIV3/Ad/HBD6
groups combined were significantly increased compared to that in the
PIV3 group. , P  0.05 compared with the results for the PIV3 group.
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and lung injury (22, 30). The increases seen here were likely a
coordinated response to the exacerbated inflammation and
injury associated with inoculation of the Ad vector and exac-
erbated PIV3 infection.
The effect of HBD6 expression in vivo on PIV3 infection was
unanticipated, as it tended to be proinflammatory and aggra-
vated the overall clinical situation. Microscopically, neutrophil
infiltration was increased in the PIV3/Ad/HBD6 group, and
this was confirmed by morphometry, in which the neutrophil
density was increased (P  0.05) compared with those in either
the PIV3 or the PIV3/Ad group. The clinical scores for body
temperature and respiration rates were increased for the PIV3/
Ad/HBD6 group compared with those for the control group
and with slight increases compared with those for the PIV3/Ad
group. While beta-defensins are increasingly known for their
antimicrobial properties, they have additional functions, such
as leukocyte chemotaxis and immunomodulation (30). Re-
cently, HBD2 was shown to function in vitro as a chemoattrac-
tant for TNF--primed neutrophils, and the HBD2 ligand in-
teraction with CC-chemokine-receptor-6 (CCR6) was
considered the mechanism for chemotaxis (25). TNF- expres-
sion is an early consequence of pulmonary Ad-mediated gene
therapy and may prime the neutrophils for CCR6-mediated
chemotaxis (40). HBD6 expression in these lambs both stimu-
lated increased neutrophilic infiltrates and accentuated the
clinical parameters of PIV3 disease without decreasing the
activity of PIV3; rather, HBD6 expression accentuated the
activity of PIV3. Although HBD6 expression is the likely
source for these events, a specific interaction between the Ad
vector and HBD6 expression cannot be ruled out. While the
efficacy of HBD6 against pathogenic organisms has not been
established, this study did show for the first time the in vivo
recruitment of neutrophils by beta-defensin expression and
that HBD6 expression during gene therapy results in biological
activity in the neonatal lamb lung.
Ad-mediated gene therapy in the lung has been hindered by
the inflammatory response that it generates. In this study a
high concentration of Ad (23, 26) was used for transfection,
which accentuated the activity of PIV3. Recent technological
advances, such as pretreatment of airways with sodium caprate
or complexing of Ad with DEAE dextran, have been used to
provide a means of reducing the Ad titer required and thus
minimizing the adverse effects (12). Another limitation of this
study is the small number of lambs used in each group, a
common problem associated with work with large animals,
which sometimes makes the finding of statistical significance
challenging due to interanimal variations (24). However, stud-
ies with large animals (as in this study) can provide novel
insights into disease mechanisms not readily observed in ro-
dent or other laboratory animal models (14). For the neonatal
lamb study we used an ovine isolate of PIV3 which is compa-
rable to human PIV3 in terms of the disease and the lesions
that it causes (7, 15, 20). This is the first study to show that
high-dose Ad gene therapy may exacerbate a concurrent PIV3
infection, a concern that needs to be further addressed for
future Ad gene therapy. Additionally, this is the first study to
show that in vivo HBD6 expression has biological activity,
specifically, neutrophil recruitment and mild aggravation of
concurrent PIV3 infection.
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